CPAP vs Oral Appliance Therapy: A Decision Framework

The standard answer for someone diagnosed with obstructive sleep apnea is CPAP. The American Academy of Sleep Medicine (AASM) considers it first-line treatment for moderate to severe OSA. But CPAP also has one of the lowest adherence rates of any common treatment in chronic medicine. Somewhere between 30 and 50% of patients abandon it within the first year, depending on the study and the population.

The alternative most commonly raised is oral appliance therapy (OAT), which is more comfortable for many patients but is also less effective than CPAP head-to-head. The decision between them is not as simple as "which works better." It is closer to "which is most likely to actually deliver clinical benefit for a specific patient." This guide walks through the AASM and AADSM positions, the adherence data, the candidacy considerations, and the framework most clinicians use to think through CPAP versus OAT.

What CPAP actually is, and what it does

CPAP (Continuous Positive Airway Pressure) is a mask connected to a small bedside machine that pushes air into your airway throughout the night. The pressure splints the upper airway open, preventing the collapse that causes obstructive apneas and hypopneas. The setup includes the machine, a humidifier (usually integrated), a hose, and a mask. Mask options include nasal masks (covering the nose), nasal pillows (sitting at the nostrils), and full-face masks (covering nose and mouth).

CPAP is highly effective when worn. AASM defines adequate use as at least 4 hours per night on at least 70% of nights. Among patients who reach this threshold, AHI typically drops to under 5 (the normal range) regardless of pretreatment severity. Cardiovascular markers, daytime sleepiness scores, and sleep architecture all tend to improve over months of consistent use.

The catch is the adherence problem. The 4-hour, 70%-of-nights threshold is what insurers use to qualify continued coverage, but real-world data suggests a meaningful fraction of CPAP users either never reach that threshold or fall off it after the initial novelty period. Discomfort, claustrophobia, mask leak, dryness, and partner complaints are common reasons cited.

What oral appliance therapy actually is

OAT uses a custom-fitted dental device that advances the lower jaw forward during sleep, opening the airway from above. The most common type is the mandibular advancement device (MAD), which looks like a two-part athletic mouthguard (upper and lower) connected by an adjustment mechanism that allows the lower piece to be incrementally advanced.

OAT requires fitting by a dentist trained in dental sleep medicine. AADSM credentials this specialty, and an AADSM-credentialed sleep dentist is the appropriate provider. The custom fit takes a couple of visits and includes a titration period during which the jaw advancement is gradually increased while symptoms and efficacy are monitored. Many sleep dentists conduct a follow-up sleep study (often HSAT-based) after titration to confirm AHI reduction.

The mechanism is different from CPAP. CPAP applies external pressure to splint the airway. OAT changes anatomy by repositioning the lower jaw and tongue base forward. Both work in principle by preventing airway collapse, but in patients with predominantly tongue-base obstruction or hypopharyngeal collapse, mandibular advancement may be less effective than CPAP. In patients with retrognathia (a set-back lower jaw) or mild-to-moderate OSA without complex anatomy, OAT can be highly effective.

What the evidence says about effectiveness

The head-to-head evidence is reasonably clear. CPAP reduces AHI more aggressively than OAT in randomized comparison trials. A typical comparison: CPAP brings AHI from baseline 25 to 3 to 5; OAT brings the same baseline 25 to 8 to 12. CPAP is more efficacious per night worn.

But the AHI comparison is not the whole clinical story. Several patient-reported outcomes (daytime sleepiness measured by the Epworth Sleepiness Scale, quality-of-life measures, and patient preference) often favor OAT or show non-inferiority. Some of this is the adherence story: a treatment that you actually use beats a treatment that you abandon. Some of it is comfort, mobility, and partner-relationship effects.

For mild to moderate OSA (AHI 5 to 29), both AADSM and AASM consider OAT a legitimate alternative to CPAP when the patient prefers it or cannot tolerate CPAP. For severe OSA (AHI 30 or higher), CPAP is the preferred first-line; OAT moves to second-line in patients who fail or cannot tolerate CPAP.

Adherence: the underappreciated variable

CPAP adherence is one of the most-studied compliance problems in chronic medical care. Estimates vary by study population and follow-up duration, but a reasonable summary is: roughly half of patients prescribed CPAP are using it adequately (the 4-hour, 70%-of-nights threshold) at one year. A meaningful additional fraction has abandoned it entirely or uses it inconsistently.

OAT adherence is higher in most studies. Regular nightly use rates in the 70 to 80% range are typical, with most adherence attrition happening in the first 3 to 6 months and stabilizing after that. The combination of (a) the device being smaller and quieter, (b) no hose or machine to disturb a partner, (c) no mask discomfort, and (d) ease of travel, all contribute.

The clinically useful framing is product, not factor. A treatment's effective AHI reduction is approximately per-night AHI reduction multiplied by the fraction of nights actually used. CPAP at 50% adherence may deliver less total respiratory improvement than OAT at 80% adherence, even if CPAP is more effective per night worn. This product framing, sometimes called "mean disease alleviation," is part of how AADSM positions OAT in shared-decision-making conversations.

Candidacy for oral appliance therapy

Not every OSA patient is a candidate for OAT. Several factors matter.

Dental health. OAT requires enough functional teeth to anchor the device. Patients with significant tooth loss, advanced periodontal disease, or extensive dental work may not be candidates without preparatory work. A pre-OAT dental exam catches this.

Jaw structure. Patients with severe retrognathia, very narrow palate, or large tongue may benefit more or less from OAT depending on which anatomic factor is driving their obstruction. A sleep dentist evaluates this.

TMJ status. Pre-existing temporomandibular joint dysfunction is a relative contraindication. OAT can aggravate TMJ symptoms in some patients, and a sleep dentist screens for this before fitting.

Severity. As above, OAT is more effective for mild and moderate OSA than for severe. For AHI 30 or higher, OAT is second-line by AASM guidelines.

Patient preference and adherence likelihood. A patient who has tried CPAP for months and refuses to continue is a different OAT candidate than a CPAP-naive patient. The first patient's OAT use is almost certainly going to exceed their CPAP use, which materially affects expected clinical benefit.

Insurance and cost. OAT is typically less covered by insurance than CPAP. Out-of-pocket costs for a custom MAD with proper titration sit in the $1,500 to $3,000 range in 2026, with significant geographic and insurance variability. Some insurers cover OAT only when CPAP has been tried and failed.

A decision framework

Most clinicians end up using some version of the framework below.

Severe OSA (AHI 30 or higher). Start with CPAP per AASM guidelines. If CPAP fails or is refused, consider OAT as second-line, or combination therapy (some patients do well on CPAP plus OAT, or on alternating use depending on travel and partner situations).

Moderate OSA (AHI 15 to 29). CPAP is the standard recommendation, but OAT is a legitimate alternative if the patient strongly prefers it or has factors making CPAP success unlikely.

Mild OSA (AHI 5 to 14). Both OAT and CPAP are acceptable first-line options. Patient preference, symptom severity, and anatomic factors drive the choice. Positional therapy, weight management, and treatment of nasal congestion are often discussed alongside.

Across all severities, two patient factors weigh heavily. First, the patient's likelihood of adhering to CPAP, which is often estimable from initial trial periods or from known factors like claustrophobia, partner conflict, work travel patterns, or prior negative experiences with face masks. Second, anatomic factors making OAT more or less likely to work (jaw position, dental health, TMJ status).

The decision is rarely "which treatment is best in the abstract." It is "which treatment is most likely to actually deliver clinical benefit for this specific patient." That answer can be CPAP, OAT, or a sequenced or combined approach.

What to do with this

Before your treatment conversation, read your own report carefully and think about your own situation. Your AHI severity is one input. Your symptoms are another. Your living situation (partner, travel, work) is a third. Your dental health is a fourth. Your tolerance for face devices is a fifth.

If you are leaning toward OAT and your physician has not raised it, ask. If you have tried CPAP and given up on it, OAT may be a legitimate next step that has not been offered. If you are at moderate-to-severe AHI and your physician recommends CPAP without discussing OAT, asking about it is reasonable. AADSM considers a CPAP-vs-OAT conversation appropriate at moderate AHI.

For a plain-English read on what your specific AHI tier suggests in terms of first-line treatment and what the next decisions on the table look like, use the AHI Interpreter.

The treatment that works for you is the treatment you will actually use. The data backs this up. Make the choice with full information, then commit to whichever one earns your adherence.